Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biocardia Inc (BCDA)

Biocardia Inc (BCDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,861
  • Shares Outstanding, K 25,914
  • Annual Sales, $ 1,350 K
  • Annual Income, $ -11,910 K
  • 60-Month Beta 1.50
  • Price/Sales 14.80
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BCDA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.62
  • Most Recent Earnings $-0.12 on 11/08/23
  • Latest Earnings Date 03/27/24 [AMC]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 264.41% ( +108.31%)
  • Historical Volatility 100.50%
  • IV Percentile 52%
  • IV Rank 25.73%
  • IV High 1,024.75% on 12/08/23
  • IV Low 1.02% on 01/29/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 9
  • Volume Avg (30-Day) 66
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 900
  • Open Int (30-Day) 1,446

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.11
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.12
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3709 +9.73%
on 03/12/24
0.5900 -31.02%
on 03/04/24
-0.1160 (-22.18%)
since 02/28/24
3-Month
0.3709 +9.73%
on 03/12/24
0.7193 -43.42%
on 01/03/24
-0.2480 (-37.86%)
since 12/28/23
52-Week
0.3600 +13.06%
on 11/01/23
2.9199 -86.06%
on 06/21/23
-1.7630 (-81.24%)
since 03/28/23

Most Recent Stories

More News
BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -30.77% and 81.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BCDA : 0.4070 (-2.89%)
EVGN : 0.7500 (+2.01%)
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -26.83% and 62.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

MRSN : 4.48 (-0.22%)
BCDA : 0.4070 (-2.89%)
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ITCI : 69.20 (-0.75%)
BCDA : 0.4070 (-2.89%)
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Food and Drug Administration (FDA) approval...

BCDA : 0.4070 (-2.89%)
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BCDA : 0.4070 (-2.89%)
URGN : 15.00 (+0.27%)
BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know

BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BCDA : 0.4070 (-2.89%)
Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ALEC : 6.02 (-0.99%)
BCDA : 0.4070 (-2.89%)
BioCardia Reports Second Quarter 2022 Business Highlights And Financial Results

SUNNYVALE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 0.4070 (-2.89%)
YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Lags Revenue Estimates

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -38.24% and 5.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

YMAB : 16.26 (-1.45%)
BCDA : 0.4070 (-2.89%)
BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022

SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 0.4070 (-2.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BioCardia Inc. is engaged in developing regenerative biologic therapies to treat cardiovascular disease. The company's product candidate consists of CardiAMP(TM), CardiALLO(TM) and Helix Biotherapeutic Delivery System(TM) in clinical development stage. BioCardia Inc. is headquartered in San Carlos, California....

See More

Key Turning Points

3rd Resistance Point 0.4430
2nd Resistance Point 0.4290
1st Resistance Point 0.4180
Last Price 0.4070
1st Support Level 0.3930
2nd Support Level 0.3790
3rd Support Level 0.3680

See More

52-Week High 2.9199
Fibonacci 61.8% 1.9420
Fibonacci 50% 1.6400
Fibonacci 38.2% 1.3379
Last Price 0.4070
52-Week Low 0.3600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar